Our diluted share count increased by approximately 2,000,000 shares in Q2 from Q1. This was primarily driven by a high AVEKO share price, which increased the diluted share count associated with our 2029 convertible notes. Now moving to the balance sheet and cash flow highlights. We ended the quarter with cash and short term investments of $305,000,000 a sequential increase of $8,000,000 From a working capital perspective, our accounts receivable declined by $14,000,000 to $92,000,000 Inventory increased slightly by $2,000,000 to $245,000,000 and accounts payable declined by $7,000,000 to $47,000,000 Customer deposits included within contract liabilities on the balance sheet declined by $13,000,000 to $59,000,000 Cash flow from operations came in at $8,000,000 and CapEx $3,000,000 Now turning to Q3 non GAAP guidance. Q3 revenue is expected between $170,000,000 $190,000,000 By market, we expect growth sequentially in semiconductor and similar levels of revenue for the remaining markets.